Please Wait.....
Report
APAC Uterine Cancer Diagnostics Market - Industry Trends and Forecast to 2030
Market Report I 2023-01-01 I 455 Pages I Data Bridge Market Research
Asia Pacific uterine cancer diagnostics market is projected to register a CAGR of 10.8% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.
Market Segmentation:
Asia-Pacific Uterine Cancer Diagnostics Market, By Diagnostic Type (Instrument Based and Procedure Based), Type (Endometrial Cancer And Uterine Sarcoma), Age Group (<30, 31-40, 41-50, 51-60 And >60), End User (Hospitals, Diagnostic Centres, Cancer Research Centre, Ambulatory Surgical Centres, Specialized Clinics, and Others), Distribution Channel (Direct Tender, Third Party Distributors, and Others), Country (Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific) Industry Trends and Forecast to 2030
Some of the major factors contributing to the growth of the Asia Pacific uterine cancer diagnostics market are:
- Increasing uterine cancer patients among the women population
- Rise in technological advancement for uterine cancer diagnostic
Market Players
The key market players operating in the Asia Pacific uterine cancer diagnostics market are:
- F-Hoffmann La Roche Ltd.
- Siemens Healthcare Private Limited
- Narang Medical Limited
- ESAOTE SPA
- Olympus Corporation
- Integra LifeSciences
- Canon Medical Systems ANZ Pty Limited.
- KARL STORZ SE & Co. KG
- Stryker
- Guzip Biomarkers Corporation
- General Electric Company
- FUJIFILM Corporation
- Koninklijke Philips N.V.
- B. Braun SE
- Jalal Surgical
TABLE OF CONTENTS
1 INTRODUCTION 117
1.1 OBJECTIVES OF THE STUDY 117
1.2 MARKET DEFINITION 117
1.3 OVERVIEW OF THE ASIA PACIFIC UTERINE CANCER DIAGNOSTIC MARKET 117
1.4 CURRENCY AND PRICING 119
1.5 LIMITATIONS 119
1.6 MARKETS COVERED 119
2 MARKET SEGMENTATION 127
2.1 MARKETS COVERED 127
2.2 GEOGRAPHICAL SCOPE 128
2.3 YEARS CONSIDERED FOR THE STUDY 129
2.4 DBMR TRIPOD DATA VALIDATION MODEL 130
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 133
2.6 MULTIVARIATE MODELLING 134
2.7 MARKET APPLICATION COVERAGE GRID 135
2.8 INSTRUMENT BASED LIFELINE CURVE 136
2.9 DBMR MARKET POSITION GRID 137
2.10 VENDOR SHARE ANALYSIS 139
2.11 SECONDARY SOURCES 140
2.12 ASSUMPTIONS 140
3 EXECUTIVE SUMMARY 141
4 PREMIUM INSIGHTS 144
4.1 PESTEL ANALYSIS 145
4.2 PORTER'S FIVE FORCES 146
4.3 PATENT ANALYSIS OF ASIA PACIFIC UTERINE CANCER DIAGNOSTICS MARKET 147
4.4 REIMBURSEMENT SCENARIO 148
4.5 INDUSTRY INSIGHTS: 149
4.6 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES 149
4.7 PRICING STRATEGIES 149
4.8 CONCLUSION 150
4.9 PREVALENCE, INCIDENCE, AND MORTALITY RATE OF UTERINE CANCER 151
4.10 COST OF UTERINE CANCER PROCEDURE 153
5 REGULATORY FRAMEWORK 154
6 MARKET OVERVIEW 156
6.1 DRIVERS 158
6.1.1 TECHNOLOGICAL ADVANCEMENTS IN UTERINE CANCER DIAGNOSTICS 158
6.1.2 RISING DEMAND FOR MINIMALLY INVASIVE ADVANCED SCREENING TECHNIQUES 158
6.1.3 RISING AWARENESS TOWARDS UTERINE CANCER 159
6.1.4 RISING IMPORTANCE OF WOMEN'S HEALTH 159
6.2 RESTRAINTS 160
6.2.1 HIGH RISK COMPLICATIONS DURING DIAGNOSTIC TESTS 160
6.2.2 LACK OF SKILLED PROFESSIONALS FOR PROPER DIAGNOSIS OF UTERINE CANCER 160
6.3 OPPORTUNITIES 161
6.3.1 INCREASING PREVALENCE OF UTERINE CANCER 161
6.3.2 RISE IN ADOPTION OF SEDENTARY LIFESTYLE 161
6.3.3 GROWTH IN MENSTRUAL COMPLICATIONS 162
6.4 CHALLENGES 162
6.4.1 LACK OF DIAGNOSTIC INFRASTRUCTURE 162
6.4.2 HIGH COST OF IMAGING SYSTEMS 163
7 ASIA PACIFIC UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE 164
7.1 OVERVIEW 165
7.2 INSTRUMENT-BASED 168
7.2.1 ULTRASOUND SCANNING 169
7.2.1.1 SYSTEMS 169
7.2.1.2 ABDOMINAL ULTRASOUND SCANNING 170
7.2.1.3 TRANSVAGINAL ULTRASOUND SCANNING 170
7.2.1.4 ACCESSORIES 170
7.2.2 IMAGING DEVICES 170
7.2.2.1 CT/PET (POSITRON EMISSION TOMOGRAPHY) SCAN 171
7.2.2.2 MAGNETIC RESONANCE IMAGING (MRI) 171
7.2.2.3 COMPUTED TOMOGRAPHY (CT) SCAN 171
7.2.2.4 OTHERS 171
7.2.3 TESTS 172
7.2.3.1 BLOOD TESTS 172
7.2.3.1.1 COMPLETE BLOOD COUNT 172
7.2.3.1.2 CA125 MARKER BLOOD TEST 172
7.2.3.2 URINE TESTS 173
7.2.3.3 OTHER TESTS 173
7.2.4 OTHERS 173
7.3 PROCEDURE BASED 173
7.3.1 ENDOMETRIAL BIOPSY 174
7.3.2 HYSTEROSCOPY 174
7.3.3 DILATION & CURETTAGE 174
7.3.4 CYSTOSCOPY 174
7.3.5 PROCTOSCOPY 175
7.3.6 OTHERS 175
8 ASIA PACIFIC UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE 176
8.1 OVERVIEW 177
8.2 ENDOMETRIAL CANCER 180
8.2.1 SEROUS ADENOCARCINOMA 181
8.2.1.1 INSTRUMENT-BASED 181
8.2.1.1.1 ULTRASOUND SCANNING 182
8.2.1.1.2 IMAGING DEVICES 182
8.2.1.1.3 TESTS 182
8.2.1.1.4 OTHERS 182
8.2.1.2 PROCEDURE-BASED 183
8.2.1.2.1 ENDOMETRIAL BIOPSY 183
8.2.1.2.2 HYSTEROSCOPY 183
8.2.1.2.3 DILATION & CURETTAGE 183
8.2.1.2.4 CYSTOSCOPY 183
8.2.1.2.5 PROCTOSCOPY 183
8.2.1.2.6 OTHERS 184
8.2.2 ADENOSQUAMOUS CARCINOMA 184
8.2.2.1 INSTRUMENT-BASED 184
8.2.2.1.1 ULTRASOUND SCANNING 184
8.2.2.1.2 IMAGING DEVICES 185
8.2.2.1.3 TESTS 185
8.2.2.1.4 OTHERS 185
8.2.2.2 PROCEDURE-BASED 185
8.2.2.2.1 ENDOMETRIAL BIOPSY 185
8.2.2.2.2 HYSTEROSCOPY 185
8.2.2.2.3 DILATION & CURETTAGE 186
8.2.2.2.4 CYSTOSCOPY 186
8.2.2.2.5 PROCTOSCOPY 186
8.2.2.2.6 OTHERS 186
8.2.3 UTERINE CARCINOSARCOMA 186
8.2.3.1 INSTRUMENT-BASED 186
8.2.3.1.1 ULTRASOUND SCANNING 187
8.2.3.1.2 IMAGING DEVICES 187
8.2.3.1.3 TESTS 187
8.2.3.1.4 OTHERS 187
8.2.3.2 PROCEDURE-BASED 188
8.2.3.2.1 ENDOMETRIAL BIOPSY 188
8.2.3.2.2 HYSTEROSCOPY 188
8.2.3.2.3 DILATION & CURETTAGE 188
8.2.3.2.4 CYSTOSCOPY 188
8.2.3.2.5 PROCTOSCOPY 188
8.2.3.2.6 OTHERS 189
8.2.4 PRIMARY PURE SQUAMOUS CELL CARCINOMA OF THE ENDOMETRIUM 189
8.2.4.1 INSTRUMENT-BASED 189
8.2.4.1.1 ULTRASOUND SCANNING 189
8.2.4.1.2 IMAGING DEVICES 190
8.2.4.1.3 TESTS 190
8.2.4.1.4 OTHERS 190
8.2.4.2 PROCEDURE-BASED 190
8.2.4.2.1 ENDOMETRIAL BIOPSY 190
8.2.4.2.2 HYSTEROSCOPY 190
8.2.4.2.3 DILATION & CURETTAGE 191
8.2.4.2.4 CYSTOSCOPY 191
8.2.4.2.5 PROCTOSCOPY 191
8.2.4.2.6 OTHERS 191
8.3 UTERINE SARCOMA 191
8.3.1 LEIOMYOSARCOMA 192
8.3.1.1 INSTRUMENT-BASED 192
8.3.1.1.1 ULTRASOUND SCANNING 193
8.3.1.1.2 IMAGING DEVICES 193
8.3.1.1.3 TESTS 193
8.3.1.1.4 OTHERS 193
8.3.1.2 PROCEDURE-BASED 194
8.3.1.2.1 ENDOMETRIAL BIOPSY 194
8.3.1.2.2 HYSTEROSCOPY 194
8.3.1.2.3 DILATION & CURETTAGE 194
8.3.1.2.4 CYSTOSCOPY 194
8.3.1.2.5 PROCTOSCOPY 194
8.3.1.2.6 OTHERS 195
8.3.2 ENDOMETRIAL STROMAL SARCOMA 195
8.3.2.1 INSTRUMENT-BASED 195
8.3.2.1.1 ULTRASOUND SCANNING 195
8.3.2.1.2 IMAGING DEVICES 196
8.3.2.1.3 TESTS 196
8.3.2.1.4 OTHERS 196
8.3.2.2 PROCEDURE-BASED 196
8.3.2.2.1 ENDOMETRIAL BIOPSY 196
8.3.2.2.2 HYSTEROSCOPY 196
8.3.2.2.3 DILATION & CURETTAGE 197
8.3.2.2.4 CYSTOSCOPY 197
8.3.2.2.5 PROCTOSCOPY 197
8.3.2.2.6 OTHERS 197
8.3.3 UNDIFFERENTIATED SARCOMA 197
8.3.3.1 INSTRUMENT-BASED 198
8.3.3.1.1 ULTRASOUND SCANNING 198
8.3.3.1.2 IMAGING DEVICES 198
8.3.3.1.3 TESTS 198
8.3.3.1.4 OTHERS 198
8.3.3.2 PROCEDURE-BASED 199
8.3.3.2.1 ENDOMETRIAL BIOPSY 199
8.3.3.2.2 HYSTEROSCOPY 199
8.3.3.2.3 DILATION & CURETTAGE 199
8.3.3.2.4 CYSTOSCOPY 199
8.3.3.2.5 PROCTOSCOPY 200
8.3.3.2.6 OTHERS 200
9 ASIA PACIFIC UTERINE CANCER DIAGNOSTICS MARKET, BY AGE GROUP 201
9.1 OVERVIEW 202
9.2 >60 YEARS 205
9.3 51-60 YEARS 206
9.4 41-50 YEARS 207
9.5 31-40 YEARS 208
9.6 <30 YEARS 209
10 ASIA PACIFIC UTERINE CANCER DIAGNOSTICS MARKET, BY END USER 210
10.1 OVERVIEW 211
10.2 HOSPITALS 214
10.3 DIAGNOSTIC CENTERS 215
10.4 CANCER RESEARCH CENTERS 216
10.5 AMBULATORY SURGICAL CENTERS 217
10.6 SPECIALIZED CLINICS 218
10.7 OTHERS 219
11 ASIA PACIFIC UTERINE CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 220
11.1 OVERVIEW 221
11.2 DIRECT TENDER 224
11.3 THIRD PARTY DISTRIBUTORS 225
11.4 OTHERS 226
12 ASIA PACIFIC UTERINE CANCER DIAGNOSTICS MARKET, BY REGION 227
12.1 ASIA-PACIFIC 228
12.1.1 CHINA 245
12.1.2 JAPAN 258
12.1.3 INDIA 271
12.1.4 AUSTRALIA 284
12.1.5 TAIWAN 297
12.1.6 NEW ZEALAND 310
12.1.7 SOUTH KOREA 323
12.1.8 SINGAPORE 336
12.1.9 INDONESIA 349
12.1.10 PHILIPPINES 362
12.1.11 VIETNAM 375
12.1.12 THAILAND 388
12.1.13 MALAYSIA 400
12.1.14 REST OF ASIA PACIFIC 413
13 ASIA PACIFIC UTERINE CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE 414
13.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC 414
14 SWOT ANALYSIS 415
15 COMPANY PROFILE 416
15.1 KONINKLIJKE PHILIPS N.V. 416
15.1.1 COMPANY SNAPSHOT 416
15.1.2 REVENUE ANALYSIS 416
15.1.3 COMPANY SHARE ANALYSIS 417
15.1.4 PRODUCT PORTFOLIO 417
15.1.5 RECENT DEVELOPMENTS 417
15.2 CANON MEDICAL SYSTEMS ANZ PTY LIMITED. 419
15.2.1 COMPANY SNAPSHOT 419
15.2.2 COMPANY SHARE ANALYSIS 419
15.2.3 PRODUCT PORTFOLIO 420
15.2.4 RECENT DEVELOPMENTS 420
15.3 GENERAL ELECTRIC COMPANY 421
15.3.1 COMPANY SNAPSHOT 421
15.3.2 REVENUE ANALYSIS 421
15.3.3 COMPANY SHARE ANALYSIS 422
15.3.4 PRODUCT PORTFOLIO 422
15.3.5 RECENT DEVELOPMENTS 422
15.4 SIEMENS HEALTHCARE GMBH 424
15.4.1 COMPANY SNAPSHOT 424
15.4.2 REVENUE ANALYSIS 424
15.4.3 COMPANY SHARE ANALYSIS 425
15.4.4 PRODUCT PORTFOLIO 425
15.4.5 RECENT DEVELOPMENTS 425
15.5 FUJIFILM CORPORATION 426
15.5.1 COMPANY SNAPSHOT 426
15.5.2 REVENUE ANALYSIS 426
15.5.3 COMPANY SHARE ANALYSIS 427
15.5.4 PRODUCT PORTFOLIO 427
15.5.5 RECENT DEVELOPMENTS 427
15.6 AED.MD 429
15.6.1 COMPANY SNAPSHOT 429
15.6.2 PRODUCT PORTFOLIO 429
15.6.3 RECENT DEVELOPMENTS 429
15.7 ARQUER DIAGNOSTICS LTD 430
15.7.1 COMPANY SNAPSHOT 430
15.7.2 PRODUCT PORTFOLIO 430
15.7.3 RECENT DEVELOPMENTS 430
15.8 B. BRAUN SE 431
15.8.1 COMPANY SNAPSHOT 431
15.8.2 PRODUCT PORTFOLIO 431
15.8.3 RECENT DEVELOPMENTS 431
15.9 ESAOTE SPA 432
15.9.1 COMPANY SNAPSHOT 432
15.9.2 PRODUCT PORTFOLIO 432
15.9.3 RECENT DEVELOPMENTS 432
15.10 F. HOFFMANN-LA ROCHE LTD 434
15.10.1 COMPANY SNAPSHOT 434
15.10.2 REVENUE ANALYSIS 434
15.10.3 PRODUCT PORTFOLIO 435
15.10.4 RECENT DEVELOPMENTS 435
15.11 GRAIL 436
15.11.1 COMPANY SNAPSHOT 436
15.11.2 PRODUCT PORTFOLIO 436
15.11.3 RECENT DEVELOPMENTS 436
15.12 GUZIP BIOMARKERS CORPORATION 438
15.12.1 COMPANY SNAPSHOT 438
15.12.2 PRODUCT PORTFOLIO 438
15.12.3 RECENT DEVELOPMENTS 438
15.13 INTEGRA LIFESCIENCES 439
15.13.1 COMPANY SNAPSHOT 439
15.13.2 REVENUE ANALYSIS 439
15.13.3 PRODUCT PORTFOLIO 440
15.13.4 RECENT DEVELOPMENTS 440
15.14 JALAL SURGICAL 441
15.14.1 COMPANY SNAPSHOT 441
15.14.2 PRODUCT PORTFOLIO 441
15.14.3 RECENT DEVELOPMENTS 441
15.15 KARL STORZ SE & CO. KG 442
15.15.1 COMPANY SNAPSHOT 442
15.15.2 PRODUCT PORTFOLIO 442
15.15.3 RECENT DEVELOPMENTS 443
15.16 MEDTRONIC 444
15.16.1 COMPANY SNAPSHOT 444
15.16.2 REVENUE ANALYSIS 444
15.16.3 PRODUCT PORTFOLIO 445
15.16.4 RECENT DEVELOPMENTS 445
15.17 NARANG MEDICAL LIMITED 446
15.17.1 COMPANY SNAPSHOT 446
15.17.2 PRODUCT PORTFOLIO 446
15.17.3 RECENT DEVELOPMENTS 446
15.18 OLYMPUS CORPORATION 447
15.18.1 COMPANY SNAPSHOT 447
15.18.2 REVENUE ANALYSIS 447
15.18.3 PRODUCT PORTFOLIO 448
15.18.4 RECENT DEVELOPMENTS 448
15.19 STRYKER 449
15.19.1 COMPANY SNAPSHOT 449
15.19.2 REVENUE ANALYSIS 449
15.19.3 PRODUCT PORTFOLIO 450
15.19.4 RECENT DEVELOPMENTS 450
15.20 SURTEX INSTRUMENTS LIMITED. 451
15.20.1 COMPANY SNAPSHOT 451
15.20.2 PRODUCT PORTFOLIO 451
15.20.3 RECENT DEVELOPMENTS 451
16 QUESTIONNAIRE 452
17 RELATED REPORTS 455
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security